{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Adverse Event Severity', 'Adverse events are to be graded according to the categories detailed below:', 'Mild:', 'Mild; asymptomatic or mild symptoms; clinical or diagnostic observations', 'only; intervention not indicated', 'Moderate:', 'Moderate; minimal, local, or noninvasive intervention indicated; limiting age', 'appropriate instrumental activities of daily living (eg, preparing meals,', 'shopping for groceries or clothes, using the telephone, managing money)', 'Severe:', 'Severe or medically significant but not immediately life-threatening;', 'hospitalization or prolongation of hospitalization indicated; disabling; limiting', 'self-care activities of daily living (ie, bathing, dressing and undressing, feeding', 'self, using the toilet, taking medications, and not bedridden); OR life-', 'threatening consequences; urgent intervention indicated; OR death related to', 'an AE', 'Changes in severity should be documented in the medical record to allow assessment of the', 'duration of the event at each level of severity. Adverse events characterized as intermittent', 'require documentation of the start and stop of each incidence. When changes in the severity of', 'an AE occur more frequently than once a day, the maximum severity for the experience that day', 'should be noted. If the severity category changes over a number of days, then those changes', 'should be recorded separately (with distinct onset dates).', 'Adverse event severity and seriousness are assessed independently. \"Severity\\' characterizes the', 'intensity of an AE. \"Serious\\' is a regulatory definition and serves as a guide to the Sponsor for', 'defining regulatory reporting obligations (see definition for SAE).', 'Relationship of the Adverse Event to Study Treatment', 'The relationship of each AE to study treatment should be evaluated by the Investigator using the', 'following criteria:', 'Definitely related:', 'A clinical event, including laboratory test abnormality, occurring in a plausible', 'time relationship to the medication administration, and which cannot be', 'explained by concurrent disease or other drugs or chemicals. The response to', 'withdrawal of the drug should be clinically plausible.', 'Possibly related:', 'A clinical event, including laboratory test abnormality, with a reasonable time', 'sequence to the medication administration, but which could also be explained', 'by concurrent disease or other drugs or chemicals. Information on the drug', 'withdrawal may be lacking or unclear.', 'Unlikely related:', 'A clinical event, including laboratory test abnormality, with little or no', 'temporal relationship to medication administration, and which other drugs,', 'chemicals, or underlying disease provide plausible explanations.', 'Not related:', 'A clinical event, including laboratory test abnormality that has no temporal', 'relationship to the medication or has more likely alternative etiology.', 'Property of the Sanofi Group - strictly confidential', '62', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '7.5.6.2.', 'Eliciting and Recording Adverse Events', 'Eliciting Adverse Events', 'The patient should be asked about medically relevant changes in his health since the last visit,', 'with attention to any signs and symptoms that could be consistent with thrombosis. The patient', 'should also be asked if he has been hospitalized, had any accidents, used any new medications,', 'or changed concomitant medication routines (both prescription and OTC). In addition to patient', 'observations, AEs will be documented from any clinically relevant laboratory findings, physical', 'examination findings, ECG changes, or other findings that are relevant to patient safety.', 'Recording Adverse Events', 'The Investigator is responsible for recording non-serious AEs and SAEs that are observed or', 'reported by the patient after the time when the informed consent is signed regardless of their', 'relationship to IMP through the end of study. Non-serious AEs will be followed until the end of', 'study. SAEs will be followed until satisfactory resolution, until baseline level is reached, or until', 'the SAE is considered by the Investigator to be chronic or the patient is stable, as appropriate.', 'All AEs must be recorded in the source records for the clinical study center and in the eCRF for', 'the patient, whether or not they are considered to be drug-related. Each AE must be described in', 'detail: onset time and date, description of event, severity, relationship to investigational drug,', 'action taken, and outcome (including time and date of resolution, if applicable).', 'For SAEs, record the event(s) on both the eCRF and the SAE form.', 'For AEs that are considered AESI (Section 7.5.6.1), the Sponsor or its designee should be', 'notified within 24 hours using a supplemental AESI eCRF. Additional clinical and laboratory', 'information may be collected; see Section 6.2.3.1 regarding monitoring for liver abnormalities.', 'Refer to eCRF completion guidelines for details on reporting events in the supplemental AESI', 'eCRF.', 'Since bleeding episodes are recorded as an efficacy assessment of fitusiran, these will not be', 'treated as AEs unless they meet any of the SAE criteria listed in Section 7.5.6.1. The', 'manifestation and frequency of bleeding episodes is an efficacy indicator of this study and ABR', 'is the focus of the primary and secondary efficacy analyses.', 'Recording an ISR', 'For all ISRs, the Investigator, or delegate, should submit a supplemental ISR eCRF, recording', 'additional information (eg, descriptions, onset and resolution date, severity, treatment given,', 'event outcome). An ISR is defined as a local reaction at or near the site of injection. \"At or', 'near\" the injection site includes reactions at the injection site, adjacent to the injection site, or a', 'reaction which may shift slightly away from the injection site due to gravity (eg, as may occur', 'with swelling or hematoma). Reactions with onset and resolution within 4 hours of the injection', '(eg, transient pain/burning at injection site) do not meet the study definition of ISRs, unless', 'immediate treatment is required. A systemic reaction which includes the injection site, eg,', 'generalized urticaria, other distinct entities, or conditions like lymphadenopathy that may be near', 'the injection site is not considered an ISR.', 'Property of the Sanofi Group - strictly confidential', '63', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}